Donna Bonney

Donna is an experienced Board Director, CEO and Executive across public and private health. education, and community services sectors.

 

Donna is currently CEO of True Relationships and Reproductive Health, and a Board Director at McLean Care and Sexual and Reproductive Health Australia.

 

She has previously held multiple executive leadership roles across the Mater Group including as CEO and Executive Director of Mater Education for 12 years – a large, commercial, not-for-profit Registered Training Organisation delivering accredited and non-accredited training for the health and community services workforce.

 

In 2021, she was asked to join Queensland’s COVID-19 Vaccination Taskforce, to establish and lead the Queensland’s COVID-19 Vaccination Command Centre, coordinating the roll out of the state’s COVID-19 vaccination program.

 

Donna is immediate past Board Chair of Jobs Queensland, a past Board Director at the Australasian College of Pharmacy, Chaired the Queensland Care Consortium, and was a member of the Queensland Workforce Strategy Roundtable.  She is dedicated to optimising the scope of practice for the healthcare workforce, professional skills development, and strategic workforce planning for all pharmacy professionals.

Dr Ayomide (Mide) Ogundipe

Dr Ayomide (Mide) Ogundipe is a pharmacist, researcher and educator passionate about advancing pharmacy practice through digital innovation and patient-centred care. She holds a PhD from Curtin Medical School, where her research explored the technological needs of community pharmacists to deliver modern, connected healthcare.

 

Mide is a Lecturer in Pharmacy at Curtin University and brings experience across clinical practice, academia and the health system, including roles supporting the delivery of complex digital health initiatives. She holds an Associate Fellowship with the Higher Education Academy (AFHEA) and is a Graduate of the Australian Institute of Company Directors (GAICD).

 

She is widely recognised for her leadership and contributions to the profession. She was named the 2019 MIMs PSA National Intern Pharmacist of the Year, 2023 PSA WA Early Career Pharmacist of the Year and was awarded Honorary Life Membership of the National Australian Pharmacy Students’ Association in 2026.

 

An active leader within the Pharmaceutical Society of Australia (PSA), she currently serves as the National Early Career Pharmacist (ECP) Board Director, Chair of the PSA ECP Community of Special Interest, Chair of the Project Advisory Group for the Pharmacists Code of Ethics Review and Vice President of the PSA Western Australian Branch. She also serves as a member of the PSA Membership, Products and Services Committee, and the Finance, Audit and Risk Management Committee.

 

With a clear vision for the future of pharmacy, Mide is committed to shaping practice through evidence-based innovation, collaborative leadership and the integration of digital health solutions to improve patient outcomes and elevate professional standards.

Dr Natalie Soulsby

Dr Natalie Soulsby has been a member of the SA Branch Committee for the last 5 years. Dr Natalie Soulsby has a background working as a clinical pharmacist in the acute sector prior to becoming an accredited pharmacist in 2010. She worked at the Royal Adelaide Hospital in the Multidisciplinary Ambulatory Clinic as part of the Clinical Pharmacology team. Dr Natalie Soulsby is Head of Clinical Excellence, Governance and Quality for Embedded Health Solutions, leading a team of over 90 pharmacists who provide RMMR, QUM and ACOP services to over 600 aged care homes.

 

She is dedicated to improving medication management especially in older people by helping rationalise the prescribing of medications and educating health care professionals. She has been an invited presenter at Aged Care conferences including LASA and ACSA (now Ageing Australia), and ConPharm (now CPC), AdPha and PSA. She is involved in training pharmacists, building their clinical knowledge and runs regular CPD sessions for her team. She has been recognized for her work by receiving SA Pharmacist of the Year 2016 and AACP Consultant Pharmacist of the Year 2017. In 2019 she was awarded the Advanced Pharmacist Practice credential.

 

Dr Amanda Cross

Dr Amanda Cross is a practising pharmacist and postdoctoral research fellow. Dr Amanda Cross’s research focuses on quality use of medicine, particularly evaluating innovative roles for pharmacists to support safe and effective use of medicines. Dr Amanda Cross has worked in community pharmacy and as a consultant pharmacist, and is currently investigating the roles of on-site aged care pharmacists.

 

Dr Amanda Cross was a member of the Victorian Branch Committee 2017-2021, including serving as Vice President 2018-2021. In 2019 Dr Amanda Cross was awarded the PSA Victorian Early Career Pharmacist of the year award.

A/Prof Helen Benson

A/Prof Helen Benson is an accredited consultant pharmacist with more than 20 years pharmacy experience. Her varied career has included working as a hospital pharmacist, military pharmacist in the Royal Australian Airforce, community pharmacist and as a community pharmacy owner. Currently A/Prof Helen Benson is working as a Senior Lecturer in Pharmacy Practice teaching Master of Pharmacy Students at the University of Technology Sydney. A/Prof Helen Benson has a particular interest in improving patient therapy through medication reviews and continues to work as a consultant pharmacist providing medication reviews for referring general practitioners. In 2019 A/Prof Helen Benson completed a PhD investigating the integration of pharmacists in general practice teams in Australia. A/Prof Helen Benson’s current research is focussed on expanding scope of practice within the profession to allow pharmacists to perform their role as medication experts.

Bridget Totterman

Bridget Totterman B.Pharm; GAICD, MPS  joined the PSA board in 2023.

 

Bridget is a registered pharmacist and community pharmacy owner with over 20 years’ experience in whole of business management including operations and frontline leadership.

 

She is a graduate of the Australian Institute of Company Directors (GAICD).

 

Bridget is a member of the Australian Community Pharmacy Authority (ACPA) and is a member of the Queensland branch committee for the Pharmaceutical Society of Australia.

 

Bridget was awarded with the Bowl of Hygiea – QLD Pharmacist of the Year in 2020 for outstanding leadership and change management.

 

Bridget was a member of the Steering Advisory Group (SAG) for UTIPP-Q (2020-2022) and was a vaccinating pharmacist in QPIP (2014). She is credentialed to administer injections and immunisations.

 

Bridget has completed courses in Directorships; Management; Marketing; Successful Negotiations; Human Resources and has an Associate Diploma in Speech and Drama.

A/Prof Fei Sim

A/Prof Fei Sim is the first female National President to lead PSA since its Federation in 1977. A/Prof Sim is a Senior Lecturer and the Coordinator of International Engagement in the Curtin Medical School at Curtin University, Western Australia (WA).

 

In 2020 she was also made a Fellow of the Society before being appointed as a Director on the PSA National Board in 2021. A/Prof Sim has over 14 years of clinical practice experience and is currently a practising community pharmacist and a community pharmacy proprietor. A/Prof Sim also served as PSA’s WA President from 2017 to 2021.

 

A/Prof Sim holds a Doctor of Philosophy degree in Pharmacy and a Bachelor of Pharmacy degree with First Class Honours and is a qualified pharmacist immuniser and an Accredited Mental Health First Aid Instructor. She is a Fellow of the PSA and the Higher Education Academy, and a Graduate Member of the Australian Institute of Company Directors. A/Prof Sim serves on a number of professional and academic committees.

 

A/Prof Sim was awarded the Excellence and Innovation in Teaching Award in 2014, the PSA WA Early Career Pharmacist Award in 2018 and the National Early Career Pharmacist of The Year Award in 2019, all of which are testament to her commitment to patient care, learning and teaching, leadership in pharmacy, innovation and initiative in pharmacy service delivery, as well as peer and professional engagement.

 

A/Prof Sim is an active pharmacy practice researcher and is also the recipient of a number of research grants and projects focusing on advancing the practice of pharmacy and the implementation of professional pharmacy services in community pharmacy, including the noteworthy JM O’Hara Research Fund grant from the Pharmaceutical Society of West Australia (PSWA) in 2018. Through this grant, A/Prof Sim and her team conducted and published on a feasibility study on point-of-care C-reactive protein testing in community pharmacy. It is hoped this project will contribute towards facilitating antimicrobial stewardship and advancing evidence-based community pharmacy practice to improve recognition of pharmacists’ roles and remuneration.

Prof Mark Naunton

Prof. Mark Naunton is currently the Chair of the Faculty of Health Board and Professor of Pharmacy at the University of Canberra. He teaches primarily in clinical therapeutics and pharmacy practice. His career includes: academic, community pharmacy, hospital pharmacy, and credentialed pharmacist in Tasmania, Northern Territory, and the ACT. Mark has a wide-reaching interest in the pharmacy profession and has worked internationally as a post-doctoral fellow at the University of Groningen in the Netherlands. Mark occasionally performs medication reviews works in community pharmacy.

 

Mark’s recent research has focused on expanding the scope of practice of pharmacists and has supervised several PhD candidates in two relevant areas: evaluating the impact of pharmacists working in general practice and RACFs.

 

He has previously served on the Tasmanian PSA Branch committee and the South Australian/Northern Territory PSA Branch committee.

 

Mark has been on the PSA ACT branch committee since 2017 and served on the PSA National Board since 2022. Mark graduated from the Australian Institute of Company Directors in 2022.

 

Mark has been a PSA member for >25 years and an active member of the pharmacy profession for over 25 years. He undertook one of the first clinical trials in Australia evaluating the benefits of HMRs post-discharge. He has also been involved in various evaluations of community pharmacist screening (osteoporosis) and disease management (cardiovascular disease. Mark is passionate about medication safety and firmly believes pharmacists are the most suited professional to ensure this occurs.

Caroline Diamantis

Caroline Diamantis is a passionate community pharmacist with over 30 years of experience in pharmacy ownership.

 

Shortly after completing her Bachelor of Pharmacy at Sydney University, she was able to fulfil her dream of buying her first pharmacy, where she realised the importance of differentiating pharmacists as professionals, advocating clinical pharmacy and the professional services model.

 

Caroline went on to become a director on the board of Blooms the Chemist, where she spent several years advocating for female pharmacy owners and gender diversity in industry leadership positions, and mentoring early career pharmacists (ECPs) into ownership roles with programs designed to support and engage.

 

Caroline was elected as Vice President of the NSW Pharmacy Guild in 2017. In this role she continued advocating for community pharmacy, particularly clinical pharmacy, and for pharmacists to be acknowledged and remunerated fairly for their role in primary health care and the critical difference they make to health outcomes.

 

Other Pharmacy Guild positions have included chairperson of the Viability sub-committee and Finance and Risk sub-committee, and alternate National Councillor.

 

Caroline is a passionate advocate for recognition of the profession during crisis, seeking acknowledgement and financial support from the NSW government. She is committed to addressing workforce issues, including mentorship to ECPs and support and advocacy for appropriate pharmacist salaries, and determined to achieve full scope of clinical practice.

PSA signs agreement to acquire the Australasian College of Pharmacy

Update: The acquisition was finalised on 19 December. See here for details.

The Pharmaceutical Society of Australia (PSA) is excited to announce an agreement to acquire the Australasian College of Pharmacy (ACP) was signed on 20 October 2025. The acquisition of ACP is part of PSA’s plan to expand educational opportunities, and grow PSA’s role as the premier education and training provider for pharmacists, pharmacy assistants and technicians. 

 

There are still steps to be completed before the settlement of the acquisition. It is expected that the acquisition it will be finalised by the end of the year (2025). 

Frequently Asked Questions

Why has the PSA Board decided to acquire ACP?

The decision to acquire ACP is part of the PSA Board’s broader plan to maximise member value through growth, expanding education opportunities for the profession, and securing a long-term, sustainable future for PSA as the premier training and education provider for pharmacists and pharmacy assistants and technicians.

What steps have been taken to progress the acquisition and when will it be finalised?

At the PSA Special General Meeting on 19 February 2025, PSA members voted overwhelmingly (95%) in support of constitutional amendments to enable the acquisition of the ACP. 

 

PSA proceeded to negotiate the terms of the acquisition and the finalisation of the Shares Purchase Agreement with the current shareholders of the ACP. 

 

PSA proceeded to ensure all regulatory issues were addressed. 

 

On 20 October 2025 the PSA Board voted unanimously to enter into a Share Purchase Agreement (contract) with shareholders of the ACP to formally acquire the ACP. 

 

Before final settlement occurs, additional legal matters related to the Share Purchase Agreement will be addressed, with the expectation the acquisition is finalised before the end of the calendar year. 

Will there be any changes to PSA's product offerings?

Until the acquisition is finalised, PSA’s products and services will continue unchanged. 

 

Once the acquisition has been completed, PSA’s education offering and CPD library is expected to grow as more resources can be invested in our education capabilities. 

 

PSA’s objects and mandate as the peak body representing all pharmacists will not change. This means, PSA will continue to be the body representing and supporting all pharmacists across all areas of practice. 

What does this mean for PSA members?

Until the acquisition is finalised, PSA’s products and services will continue to be provided to members unchanged.  

 

Once the acquisition has been completed, PSA’s education offering and CPD library is expected to grow as more resources can be invested in our education. 

 

PSA members can expect greater support and increased focus on high quality education to meet the growing needs of pharmacists in all areas of practice, and the broader pharmacy workforce.

Where can I find out more information if I have questions?

If you have questions regarding PSA’s acquisition of ACP, you can: 

  • call our membership team on 1300 369 772 (business hours AEDT)